Site Sponsors
  • Park Systems - Manufacturer of a complete range of AFM solutions
  • Strem Chemicals - Nanomaterials for R&D
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD

There is 1 related live offer.

Save 25% on magneTherm

Cerulean to Present on Nanopharmaceutical Platform at Two Major European Conferences

Published on November 15, 2010 at 5:04 AM

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that the Company’s senior executives will be presenting at two major European conferences to be held in Munich and Berlin, Germany.

Oliver Fetzer, Ph.D., president and chief executive officer of Cerulean, is scheduled to present at the 16th Annual BIO-Europe 2010 partnering conference, to be held in Munich, Germany. The presentation is scheduled for Tuesday, November 16, 2010, at 10:00 a.m., at the International Congress Center Munich. In his presentation, Dr. Fetzer will brief attendees on the most recent progress in Cerulean’s key programs, including its lead clinical candidate, CRLX101, and its pre-clinical docetaxel nanopharmaceutical program. Additionally, Dr. Fetzer will highlight the versatility of the company’s nanopharmaceutical platform and its potential partnering opportunities.

Cerulean Chief Medical Officer John Ryan, Ph.D., M.D., and Senior Director of Research Scott Eliasof, Ph.D., are scheduled to present at the 22nd EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics,” to be held in Berlin, Germany. The Cerulean presentations are scheduled for Thursday, November 18, 2010, at the Estrel Berlin Hotel and Convention Center. At the symposium, Dr. Ryan will detail critical findings from the completed Phase 1 clinical study of CRLX101. Specifically, Dr. Ryan will highlight observations of progression free disease of greater than six months in five advanced cancer patients who had previously relapsed and progressed on multiple lines of prior therapy. Concurrently, Dr. Eliasof’s presentation will feature results on the Company’s pre-clinical lead candidate, CRLX288, a docetaxel nanopharmaceutical, demonstrating its highly favorable tolerability, extended pharmacokinetics, and superior efficacy in a broad range of xenograft models.

Source: http://www.ceruleanrx.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit